Enzymatica
1.67
SEK
0 %
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
0%
-8.24%
-29.83%
-27.18%
-54.22%
-53.99%
-78.02%
-55.17%
-70.77%
Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.
Read moreMarket cap
405.37M SEK
Turnover
109.34K SEK
Revenue
50.9M
EBIT %
-94.42 %
P/E
-
Dividend yield-%
-
Financial calendar
18.2
2025
Annual report '24
29.4
2025
Interim report Q1'25
17.7
2025
Interim report Q2'25
ShowingAll content types
Enzymatica AB: Enzymatica announces outcome of new rights issue
Enzymatica AB: BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools